+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Pembrolizumab"

Checkpoint Inhibitors Market Report 2025 - Product Thumbnail Image

Checkpoint Inhibitors Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
Drugs for Immunotherapy Market Report 2025 - Product Thumbnail Image

Drugs for Immunotherapy Market Report 2025

  • Report
  • April 2025
  • 250 Pages
  • Global
From
Oral Cancer Treatment Market Report 2025 - Product Thumbnail Image

Oral Cancer Treatment Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
Throat Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Throat Cancer Therapeutics - Global Strategic Business Report

  • Report
  • November 2025
  • 267 Pages
  • Global
From
Gastric Cancer - Global Strategic Business Report - Product Thumbnail Image

Gastric Cancer - Global Strategic Business Report

  • Report
  • November 2025
  • 582 Pages
  • Global
From
Oral Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Oral Cancer Therapeutics - Global Strategic Business Report

  • Report
  • November 2025
  • 182 Pages
  • Global
From
Metastatic Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Metastatic Cancer Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 377 Pages
  • Global
From
From
Stomach Cancer Treatment - Global Strategic Business Report - Product Thumbnail Image

Stomach Cancer Treatment - Global Strategic Business Report

  • Report
  • November 2025
  • 371 Pages
  • Global
From
Hepatocellular Carcinoma Drugs - Global Strategic Business Report - Product Thumbnail Image

Hepatocellular Carcinoma Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 198 Pages
  • Global
From
Gynecological Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Gynecological Cancer Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 193 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Thumbnail Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • November 2025
  • 224 Pages
  • Global
From
Immune Checkpoint Inhibitors - Global Strategic Business Report - Product Thumbnail Image

Immune Checkpoint Inhibitors - Global Strategic Business Report

  • Report
  • November 2025
  • 194 Pages
  • Global
From
Liver Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Liver Cancer Drugs - Global Strategic Business Report

  • Report
  • November 2025
  • 277 Pages
  • Global
From
Antibody Drug Conjugate - Competitive Landscape, 2025 - Product Thumbnail Image

Antibody Drug Conjugate - Competitive Landscape, 2025

  • Report
  • March 2025
  • 450 Pages
  • Global
From
From
Ewing Sarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Ewing Sarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 115 Pages
  • Global
From
4-1BB Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

4-1BB Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 100 Pages
  • Global
From
Malignant Pleural Mesothelioma- Pipeline Insight, 2025 - Product Thumbnail Image

Malignant Pleural Mesothelioma- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Leiomyosarcoma - Pipeline Insight, 2025 - Product Thumbnail Image

Leiomyosarcoma - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

Pembrolizumab is a type of oncology drug used to treat certain types of cancer. It is a monoclonal antibody, which works by targeting and blocking a protein called PD-1, which is found on the surface of some cancer cells. This helps the body's immune system to recognize and attack the cancer cells. Pembrolizumab is used to treat a variety of cancers, including melanoma, non-small cell lung cancer, head and neck cancer, Hodgkin lymphoma, and urothelial carcinoma. It is also used in combination with other drugs to treat certain types of advanced or metastatic cancers. Pembrolizumab is approved by the US Food and Drug Administration (FDA) and is available in the US and other countries. It is typically administered intravenously, and the dosage and duration of treatment depend on the type and stage of cancer being treated. Some companies in the Pembrolizumab market include Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, and Roche. Show Less Read more